The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Amiot, Aurelien ^a,b,c   Mansour, Hicham ^c,d   Baumgaertner, Isabelle ^a   Delchier, Jean Charles ^a,b   Tournigand, Christophe ^a,b   Furet, Jean Pierre ^e   Carrau, Jean Pierre ^f   Canoui Poitrine, Florence ^a,b,c   Sobhani, Iradj ^a,b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c University of Paris Est Créteil   (France)

^d KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^e UMR1319 MICALIS   (France)

^f CPAM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC; K RAS PROTEIN; VIMENTIN; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; WIF1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ALX 4 GENE; ARTICLE; BACTERIAL COUNT; BACTERIUM DETECTION; CANCER SCREENING; COLONOSCOPY; COLORECTAL POLYP; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; DYSBIOSIS; FECES MICROFLORA; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OCCULT BLOOD TEST; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; URINALYSIS; VIMENTIN GENE; WIF 1 GENE; AGED; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; OCCULT BLOOD;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; REPRESSOR PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84904269291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099233     Document Type: Article

References (41)

1. Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, et al. (2013) Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteriarelated disease? Therap Adv Gastroenterol 6: 215-229.
2. Boyle P, Leon ME (2002) Epidemiology of colorectal cancer. Br Med Bull 64: 1-25. (Pubitemid 35238576)
3. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, et al. (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375: 1624-1633.
4. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, et al. (2008) Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 359: 1207-1217.
5. Muller AD, Sonnenberg A (1995) Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 123: 904-910.
6. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN (2006) Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. Jama 295: 2366-2373. (Pubitemid 43788104)
7. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, et al. (2004) Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126: 1674-1680. (Pubitemid 38736331)
8. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, et al. (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477. (Pubitemid 26400242)
9. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348: 1467-1471. (Pubitemid 26400241)
10. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371. (Pubitemid 23131388)
11. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334: 155-159. (Pubitemid 26017953)
12. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714. (Pubitemid 39665324)
13. Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014) Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and metaanalysis. Ann Intern Med 160: 171.
14. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85. (Pubitemid 30451850)
15. O'Keefe SJ, Ou J, Aufreiter S, O'Connor D, Sharma S, et al. (2009) Products of the colonic microbiota mediate the effects of diet on colon cancer risk. J Nutr 139: 2044-2048.
16. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196. (Pubitemid 27435555)
17. Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13: 679-692.
18. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD (2001) Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 61: 900-902. (Pubitemid 32174399)
19. Shivapurkar N, Gazdar AF (2010) DNA methylation based biomarkers in noninvasive cancer screening. Curr Mol Med 10: 123-132.
20. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, et al. (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13: 607-615.
21. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, et al. (2011) Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 6: e16393.
22. Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, et al. (2011) Towards the human colorectal cancer microbiome. PLoS One 6: e20447.
23. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, et al. (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338: 120-123.
24. Sobhani I, Jarrousse V, Guilemeau S, Blugeon S, Auriault ML, et al. (2011) Colon cancer patients' microbiome induces intestinal precancerous change in germ-free mice. Gut 60: A1.
25. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
26. Furet JP, Firmesse O, Gourmelon M, Bridonneau C, Tap J, et al. (2009) Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol 68: 351-362.
27. Reuther GW, Der CJ (2000) The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 12: 157-165. (Pubitemid 30142561)
28. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172; discussion 207-112.
30. Mansour H, Sobhani I (2009) Method, process, and kit for diagnosis or prognosis of colorectal cancer. WO 2009095596 A2. Paris, France.
31. Lieberman D (2009) Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 25: 422-427.
32. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561. (Pubitemid 23186645)
33. Peinado MA, Malkhosyan S, Velazquez A, Perucho M (1992) Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci U S A 89: 10065-10069.
34. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
35. Lengauer C (2003) Cancer. An unstable liaison. Science 300: 442-443.
36. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, et al. (2013) Cancer genome landscapes. Science 339: 1546-1558.
37. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, et al. (2004) Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363: 1283-1285. (Pubitemid 38496491)
38. Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I (2011) Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum 54: 876-886.
39. Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13: 800-812.
40. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, et al. (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14: 207-215.
41. Prorok-Hamon M, Friswell MK, Alswied A, Roberts CL, Song F, et al. (2013) Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut published online: doi: 10.1136/gutjnl-2013-304739.